Pennsylvania is currently home to 3463 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin
NCT04784234
Recruiting
This study is looking at changes in vision and visual function before and after a six month trial of a daily medical food called GlaucoCetin, formulated with ingredients to support and protect the optic nerve cells. Open angle glaucoma patients will be randomized to receive either a placebo or the medical food for 6 months. We hope to learn if this medical food can improve the vision of our glaucoma patients and to report the findings obtained to the general public.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
06/30/2022
Locations: Wills Eye Hospital, Glaucoma Research Center, Philadelphia, Pennsylvania
Conditions: Primary Open Angle Glaucoma
Register for Updates
Artisan Aphakia Lens for the Correction of Aphakia in Children
NCT01547442
Recruiting
The purpose of this study is to determine the safety and effectiveness of the Artisan Aphakia Lens in the treatment of aphakia in children.
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
06/24/2022
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Aphakia
Register for Updates
Artisan Aphakia Lens for the Correction of Aphakia (Secondary) in Adults
NCT01547429
Recruiting
This study will determine the safety and effectiveness of the Artisan Aphakia Lens when used as a secondary implant to correct aphakia in adults.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/24/2022
Locations: Nevyas Eye Associates, Bala-Cynwyd, Pennsylvania
Conditions: Aphakia
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Children's Hospital of Philadelphia (Pediatrics only), Philadelphia, Pennsylvania
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting
NCT04900844
Recruiting
The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.
Gender:
All
Ages:
Between 19 years and 80 years
Trial Updated:
06/16/2022
Locations: UPMC-Pinnacle, Harrisburg, Pennsylvania
Conditions: Carotid Artery Stenosis
Register for Updates
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
NCT04857489
Recruiting
The purpose of this research is to find out how the T regulatory (Treg) cells control autoimmune response in multiple sclerosis. The investigators will identify Treg molecular markers and changes in function in patients with relapse remitting multiple sclerosis (RRMS). The investigators plan to study T regulatory immune cells in the blood of RRMS patients and control subjects to examine how Treg immune cells' deficient function may be involved in the development of mulitple sclerosis.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/13/2022
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Relapse Remitting Multiple Sclerosis
Register for Updates
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
NCT02498951
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2022
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma
Register for Updates
IL-11 in the Development of Multiple Sclerosis
NCT03735823
Recruiting
Since the last submission, the investigator have further characterized the potential of IL--11 to induce encephalitogenic CD4+IL--17A+, IL--21+ and GM--CSF+ cells, which upon passive transfer induced severe RREAE with IL--17A+CCR6+ CD4+ cell, neutrophil, CD8+ and B--cell accumulation within the CNS (manuscript submitted for publication). These findings confirmed our hypothesis and further characterization of the IL--11--induced encephalitogenic CD4+ cells will be performed as planned in the gran... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/03/2022
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Multiple Sclerosis
Register for Updates
ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain
NCT03261193
Recruiting
Comparison of standard post-operative cesarean surgery pain management with regional post-op pain control.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
06/02/2022
Locations: Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Pain, Postoperative
Register for Updates
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT02847559
Recruiting
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/25/2022
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Register for Updates
Influence of Cognition on Activity and Participation in People With Stroke
NCT05392270
Recruiting
If a subject agrees to participate, the primary investigators will collect some basic information including age, height, and weight. Intake of some general questions regarding health and each subject will complete some tests that measure walking speed, cognition, and balance. During these tests participants will be asked to stand from a chair, walk up & down a staircase, walk over objects in a forward, backward, and sideways directions, walk around objects in forward and backward directions. Aft... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2022
Locations: University of the Sciences, Philadelphia, Pennsylvania
Conditions: Stroke, Cognitive Change, Neuroplasticity, Exercise Intervention, Dual Task
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Abington Neurologic Associates, Abington, Pennsylvania
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates